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Abstract
Purpose To analyze the success rate, time to passage of
tissue and subjective patient experience of a newly
implemented protocol for medical management of early
pregnancy failure (EPF) over a 2-year period.
Methods A retrospective chart review of all patients with
early pregnancy failure primarily opting for medical
management was performed. 200 mg mifepristone were
administered orally, followed by a single vaginal dose of
800 mcg misoprostol after 36–48 h. We followed-up with
our patients using a written questionnaire.
Results 167 women were included in the present study. We
observed an overall success rate of 92 %, defined as no
need for surgical management after medication adminis-
tration. We could not identify predictive values for success
in a multivariate regression analysis. Most patients (84 %)
passed tissue within 6 h after misoprostol administration.
The protocol was well tolerated with a low incidence of
side effects. Pain was managed well with sufficient anal-
gesics. Responders to the questionnaire felt adequately
informed prior to treatment and rated their overall experi-
ence as positive.
Conclusion The adaption of the institutional medical pro-
tocol resulted in a marked improvement of success rate
when compared to the previously used protocol (92 vs.
61 %). We credit this increase to the adjusted medication
schema as well as to targeted physician education on the
expected course and interpretation of outcome measures.
Our results underscore that the medical management of
EPF is a safe and effective alternative to surgical evacua-
tion in the clinical setting.
Keywords Early pregnancy failure  Medical
management  Mifepristone  Misoprostol
Introduction
Early pregnancy failure (EPF) is a common pregnancy
complication with approximately 25 % of pregnancies
ending in miscarriage and with 1 in 4 women experiencing
this problem during her reproductive lifespan [1–3]. With
the routine use of ultrasound, these pregnancy failures are
often diagnosed prior to the onset of any symptoms, such as
bleeding or cramping, and have been therefore termed
‘‘missed abortions’’. Improvements in ultrasound technol-
ogy have further enabled the subclassification of asymp-
tomatic EPF into intrauterine embryonic/fetal demise
(IUED/IUFD) and anembryonic gestation (‘‘blighted
ovum’’). In contrast, women with inevitable abortion,
incomplete abortion and completed abortion experience
cervical dilation, cramping, and bleeding during the pas-
sage of tissue that ends in miscarriage [4, 5].
Considering the psychological and physical burden of
experiencing a pregnancy failure, it is important to be able
to offer patients effective, timely, and safe management
[6, 7]. Upon the definitive diagnosis of EPF, the following
three treatment options may be considered: (1) expectant
management with follow-up; (2) surgical management with
pregnancy evacuation [cervical dilation followed by
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suction or blunt curettage (D&C)]; or (3) medical man-
agement using misoprostol or a combination of mifepris-
tone and misoprostol to induce uterine evacuation [4, 5].
Historically, surgical management was the mainstay of
management, offering prompt uterine evacuation with a
high rate of success of over 95 %. More recently, medical
management has become an established alternative option
for patients wishing to avoid surgery and its associated
operative risks, such as uterine perforation, endometritis,
injury to the cervix, and Asherman’s syndrome, as well as
potential anesthesia-related complications [4, 5, 8–11].
Medical management of EPF is routinely carried out with
the prostaglandin E1 analogue Misoprostol which induces
cervical dilation and uterine contractions, inducing the
vaginal expulsion of the failed pregnancy. Some, but not
all, clinicians administer mifepristone, a competitive pro-
gesterone antagonist, 24–48 h prior to misoprostol admin-
istration to improve the success rate by disrupting the
progesterone-mediated trophoblast-decidua interaction.
Corresponding study results are contradictory. While some
studies show promising results exceeding a success rate of
85–90 % with coexistent mifepristone use, others have
found no additional benefit whether a dose of 200 mg or
600 mg is given, at the cost of increased expense
[10, 12–17]. Unlike its beneficial use in elective termina-
tions of viable pregnancies (elective abortions), mifepris-
tone may have limited usefulness in failed pregnancy
which have lower progesterone levels [18–21].
The overall success rate of medical management quoted
in the literature is highly variable, ranging from 66–83 %
in clinical practice and even as high as 95 % in small
research studies, as summarized in Table 1. In our previous
publication of the success rate in routine clinical practice in
our university clinic, we found a disappointingly low rate
of only 61 % [14]. The reason for this discrepancy is likely
due to the great institutional variability in the medications,
their dosages, routes, and time intervals of administration
used for treatment. In addition, as shown in Table 1, the
definition of successful treatment varies greatly from study
to study, and has been defined as no presence of gestational
sac on ultrasound, termination of vaginal bleeding, or by
endometrial thickness on ultrasound [5, 22–25]. Finally,
the more experienced clinician is in the use of medical
management, the more comfortable he/she may be with
expectantly managing the patient with heavy or prolonged
bleeding post-medication administration. Less experienced
Table 1 Protocols in the literature
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clinicians may be prompted to intervene too quickly with
curettage, thus decreasing the perceived success rate.
We aimed to improve the success of medical manage-
ment of EPF in our university hospital setting by adopting
the most successful evidenced-based medication regimen
while limiting costs. In addition, we formally reviewed
with the treating physicians, the expected effects of treat-
ment (bleeding pattern and duration, cramping, and pain)
as well as the expected post-treatment ultrasound findings
and their correct interpretation. Finally, we defined stan-
dard operating procedures (SOP) to standardize and opti-
mize the clinical course of treatment and to define the
indications for surgical intervention. This treatment algo-
rithm is shown in Fig. 1.
In this study, we retrospectively analyze the success rate
of the medical management of EPF in the first 2 years upon
the implementation of the above-mentioned changes. In
addition, we report the results of a questionnaire sent to the
patients who were treated with medical management dur-
ing this time period which compared the patients’
expectations of treatment (bleeding, pain, and side effects)
to their actual experiences and inquired about their will-
ingness to choose this treatment option in the future or to
recommend it to a friend.
Materials and methods
The present retrospective study was approved by the
institutional ethics committee of the Medical University of
Innsbruck. The participants who returned the follow-up
questionnaires signed an informed consent.
As summarized in Fig. 1, according to institutional
SOPs, all patients diagnosed with a non-viable early
pregnancy are presented three options upon diagnosis: (1)
expectant management, (2) surgical management by dila-
tion and curettage (D&C), and (3) medical management
with mifepristone and misoprostol. All patients primarily
opting for medical management receive a single oral dose
of 200 mg Mifepristone on an out-patient basis and are
subsequently admitted 36–48 h later to our day-inpatient
unit. On admission, an ultrasound is performed to confirm
the continued presence of the intrauterine EPF, and
diclofenac and metogastrone are given intravenously for
prevention of pain and nausea, respectively. Subsequently,
a single dose of 800 mcg (4 Tablets of 200 mcg each)
misoprostol is administered intra-vaginally to the posterior
fornix by the treating physician. All patients are monitored
for the following 8 h for bleeding and passage of tissue
which is recorded in the electronic medical record. They
may be administered additional analgesics or antiemetics,
as necessary. In a small subset of patients, outside of the
defined SOP, an additional dose of 400 mcg Misoprostol
was administered buccally when no passage of tissue took
place after 6 h of the vaginal dose. Following the suspected
passage of the failed pregnancy, or at the latest at 5 pm
(closing time of the day-unit), a transvaginal ultrasound is
performed to guide further follow-up. If the ultrasound
shows no gestational sac present, the endometrial thickness
is less than 20 mm, and bleeding is within normal limits,
then the patient is discharged and an out-patient follow-up
visit is scheduled in 4 weeks’ time. If the gestational sac is
still visible and/or the endometrium thickness measures
more than 20 mm, and bleeding is within normal limits,
then the patient is discharged and scheduled for follow-up
in 1 week. At the 1 week appointment, a re-evaluation is
performed. If there are sonographic or clinical evidences
for ongoing EPF, then the patient can opt for another
course of misoprostol, expectant management, or surgical
management.
Using admission records, we identified all patients who
received medical management for EPF in the 2-year period
between March 1, 2013 and February 28, 2015. To be
Fig. 1 Implemented protocol
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included, the women had to have a missed abortion B12-
week gestation (intrauterine embryonic or fetal demise or
anembryonic gestation without cervical dilation or heavy
bleeding). Exclusion criteria included multiple gestation,
pregnancy with an IUD in place, gestational age[13 -
weeks by ultrasound, and the diagnosis of inevitable,
incomplete, and complete miscarriage. Patients’ charts and
electronic records were retrospectively abstracted to collect
clinical and ultrasound data at initial presentation and the
clinical course following misoprostol administration,
focusing on the time to passage of tissue, amount of
bleeding, and medications’ administered and documented
side effects. Relevant previous obstetric, gynecologic, and
medical history were recorded. Treatment success was
defined as no surgical intervention after initiation of med-
ical treatment. We calculated the overall success rate for all
women, and according to gestational age (B9 vs. C10), and
diagnosis (anembryonic gestation vs. IUED/IUFD).
Logistic regression analyses were performed to evaluate
for pre-selected predictive factors of success, using the
independent variables age, body mass index (BMI), parity,
gestational age (GA), and diagnosis.
We compared the outcomes of the present study to those
we previously reported from a retrospective review of
cases between 2006 and February 2012 prior to the
establishment of the current SOPs. We used the student’s
t test or Mann–Whitney U test to compare parametric and
non-parametric outcomes, respectively, and the Chi-square
test to compare binomial outcomes. Analyses were per-
formed using PASW Statistics for Windows, Version 18.0.
Chicago: SPSS Inc.
Finally, we followed-up with our patients by mailing
each of the women a questionnaire to be filled out and
returned in an envelope provided. The questions in this
questionnaire asked whether the treatment experience met
the women’s expectations in terms of amount and duration
of bleeding, amount of pain as well as asked how they rated
the overall experience and whether they would choose this
treatment method again and/or recommend it to a friend.
Results
We identified 167 patients who met the inclusion criteria
and were included in this study. Patient characteristics are
shown in Table 2 and are similar to those of the women
who made up the study population reported in our previous
publication [14].
153 of 167 women were successfully treated with
medical management for a cumulative success rate of 92 %
(n = 69/79 or 81 % in the first year and n = 84/88 or 97 %
in the second year). Subgroup analyses by gestational age
(B9 weeks, C10 weeks) and diagnosis (IUED/IUFD vs.
anembryonic gestation) showed no significant difference in
successful management (GA by LMP—91 vs. 88 %,
p = 0.498; GA by ultrasound—89 vs. 82 %, p = 0.468;
diagnosis—87 vs. 97 %, p = 0.081).
To identify possible predictive factors for success, we
performed a multivariate regression analysis. None of the
pre-selected independent variables were able to predict
successful treatment (Table 3).
Since this is a retrospective evaluation of routine clinical
practice, a small number of women were treated outside of
the standardized protocol by the treating physician.
Namely, in the absence of passage of tissue within 6 h of
vaginal misoprostol administration, 26 patients (16 %)
received an additional dose of 400 mcg misoprostol
bucally. Of these women, 15 passed tissue within the fol-
lowing 2–3 h, while 11 still had no passage of tissue.
In 92 cases, the exact time of the first passage of tissue
after administration of misoprostol was documented. In
77 of these women (84 %), it occurred within 6 h after
Table 2 Patient characteristics
Parameter March 2013–February 2015
N = 167
Colleselli et al. [14]
N = 168
p
Mean ± SD Median
(min.–max.)
Mean ± SD Median
(min.–max.)
Age (years) 33.2 ± 6.0 34 (18–47) 32.7 ± 6.6 33 (16–45) 0.474
BMI 23.6 ± 4.2 23.0 (15.5–37.8) 22.7 ± 3.7 22 (12.8–37.0) 0.085
Gravidity – 2 (1–9) – 2 (1–7) –
Parity – 1 (0–5) – 0 (0–5) –
GA by LMP (weeks) 10.0 ± 1.6 10 (6–15) 10.1 ± 2.1 10 (5–18) 0.756
GA by ultrasound (weeks) 7.8 ± 1.5 7 (5–12) 8.1 ± 1.8 8 (5–13) 0.343
Time to surgery after misoprostol (days) 26.1 ± 19.3 22.5 (0–57) 5.3 ± 9.6 1 (0–42) \0.001*
Expulsion time after administration of misoprostol (hours) 4.7 ± 1.8 4.3 (1.5–12.5) 8.4 ± 7.2 5.5 (1–34) \0.001*
* Statistically significant
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misoprostol administration, with a median of 4.3 h. In the
remaining 15 women, it was still within 9 h of medication
administration, since these women were discharged
without a gestational sac. Overall, the time to passage of
tissue was statistically significantly shorter than with our
previous protocol when the median time was 5.5 h. In
contrast, the time to surgical intervention was statistically
significantly longer with the revised protocol. In the few
women who needed surgical evacuation, this was per-
formed on average 26 days after medication administra-
tion, in comparison with just 5 days post-treatment
between 2006 and 2012.
In Fig. 2, we show the detailed outcomes for the
patients. 23 patients were discharged with a visible gesta-
tional sac or endometrial lining[20 mm on ultrasound.
Only 3 of these women were required a surgical inter-
vention (curettage) to be subsequently performed. In 2 of
these women this was due to persistent bleeding and in 1 of
the women due to continued presence of the gestational sac
on ultrasound. In none of these women were the surgical
intervention emergent.
Of the 143 women discharged without a gestational sac
and Endometrium\20 mm (presumed to be a completed
abortion), ten nonetheless underwent surgical intervention.
The indications for curettage in these women were sus-
pected retained products of conception on ultrasound in
eight cases and persistent bleeding in two cases. None of
these interventions were performed on an emergency basis.
None of these women opted for a repeat treatment with
misoprostol. For the total of 13 women who needed
curettage, the procedure was performed between 0 and
57 days after the administration of misoprostol, median
22.5 days. In 50 % of women, chorionic villi were
obtained, confirming retained products of conception. One
woman required a blood transfusion post-surgery for heavy
intraoperative bleeding. No blood transfusion was admin-
istered after medical management alone.
The overall rate of side effects was low. The most
common side effects reported were nausea (10 %), vom-
iting (5 %), diarrhea (4 %), cramping, and pain (59 %);
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Fig. 2 Outcome
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To gain insight into the subjective experience of our
patients, we sent all medically treated patients a question-
naire together with a pre-paid return-addressed envelope, 62
of which were returned (return rate 37 %). 92 % of ques-
tionnaire participants felt that they received sufficient writ-
ten and oral information prior to treatment. Nonetheless,
fewer than half of the women reported the duration and
amount of bleeding and pain to be consistent with expec-
tations. In 27–34 % of responders, these parameters were
more severe than expected, in the remaining responders less
than expected, as shown in Table 4. Despite these results,
65 % of responders evaluated the overall experience as
positive, with only 15 % negative and 21 % neutral ratings.
63 % of responders would opt for medical therapy again in
the case of another EPF, while only 10 % would primarily
choose surgery, and the remainder were not sure. Positive
aspects of medical management most frequently noted were
avoidance of a surgical procedure (76 %), care and support
of staff (66 %), short treatment duration (57 %), and well-
managed pain control (44 %). We saw an improvement in
responses when comparing the first year to the second year
of protocol implementation, as shown in Table 5. Due to
only five questionnaires being returned from women with
unsuccessful treatment, we were unable to make meaningful
comparisons of their treatment evaluations compared to
those treated successfully.
Discussion
The introduction of a new institutional protocol for the
medical management of EPF resulted in a marked
improvement in the success rate to 92 %, compared to the
previous success of 61 % [14]. This high success rate is
comparable to that reported in interventional studies under
research protocols summarized in Table 1. For this
improvement, we credit the use of an evidence-based
medication schema (200 mg mifepristone orally followed
by a single dose of 800 mcg misoprostol vaginally), tar-
geted physician education, as well as the adoption of SOPs.
The aim of the SOPs was to standardize the treatment
algorithm and to aid the clinician in interpreting clinical
signs and ultrasound results to plan follow-up accordingly.
Most women expelled the failed pregnancy during their
stay in our day clinic and within only a few hours after
medication administration. These data are important in
accurately counseling women regarding their expectations.
Although medical management can be safely performed as
an out-patient treatment at home, we feel it is reassuring for
the women to be monitored for bleeding and to be offered
adequate pain management [26, 27].
Of the 23 women who did not expel the tissue during the
first day of monitoring, the great majority (87 %) did so
within the following week. This is consistent with previous
studies and supports the recommendation to allow up to
7 days before subsequent re-evaluation and additional
treatment [11]. This is a safe management strategy, sup-
ported by our findings that none of the women required an
emergent surgical intervention due to heavy bleeding.
The most frequent indication for surgical intervention
was persistent vaginal bleeding despite previous passage of
the gestational sac. Very few women had sonographic
evidence of persistent products of conception as the indi-
cation for surgery. Histological evaluation confirmed the
presence if intrauterine chorionic villi in only half of the
curettage specimens. Thus, it is impossible to know whe-
ther some or most of these women would have sponta-
neously ceased bleeding without surgical intervention.
Previous studies have shown that bleeding patterns fol-
lowing medical management of EPF can be quite variable,
but prolonged bleeding exceeding 20 days is not uncom-
mon [28]. In fact, recent management strategies call for a
longer time until intervention, waiting for up to 4–6 weeks
[29].
It is reassuring that this combined protocol of mifepri-
stone and misoprostol was well tolerated with a paucity of
gastrointestinal side effects, especially when compared to
other studies [30]. This may be partly due to the prophy-
lactic administration of antiemetics prior to misoprostol
administration.
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Nonetheless, facing a non-viable pregnancy is psycho-
logically difficult for affected women. Eligible women
should, therefore, be counseled appropriately to enhance
their understanding and expectations of treatment and
psychological counseling should be offered routinely.
The study is limited by its retrospective design and lack
of randomization. Therefore, we cannot evaluate whether
the women who chose first-line medical management differ
from those who prefer surgical treatment from the outset or
from those who choose expectant management. However,
due to strong patient preferences for which treatment they
choose, a randomized study of medical vs. surgical inter-
vention will likely never be able to be conducted. The
study was conducted at a single university-based hospital,
which may potentially limit the generalizability of the
results to other treatment settings.
To further improve counseling for medical treatment, we
designed a questionnaire to investigate patients’ experiences
and satisfaction with the present protocol. Although a
detailed written informed consent and information sheet is
provided prior to treatment begin, one which the responders
deemed adequately informative, their expectations regarding
bleeding and pain were nonetheless incorrect in more than
half of cases. This highlights the importance of an individual
discussion with each patient. We did see a distinct
improvement in the accuracy of expectations when com-
paring after the first year to the second year following the
implantation of the protocol. We believe that this improve-
ment might be attributed to more clinical experience and
increasing familiarity with the SOPs, translating into more
accurate information given to the patient.
Surgical treatment of EPF is associated with the risk
factors of perforation, bleeding, anesthesia, and subsequent
Asherman’s syndrome [8]. In addition, preliminary evi-
dence shows that surgical management, especially with
dilation of the cervix and curettage, might have adverse
effects on future pregnancies [31–33]. Therefore, it is
especially important to be able to offer highly effective
medical management as an alternative to operative inter-
vention. Medical management needs to be performed using
evidence-based protocols by physicians trained in the
expected outcomes, especially regarding bleeding and pain,
and in the interpretation of ultrasound findings so as not to
intervene unnecessarily.
In a standard gamble study, Griaziosi et al. showed that
when faced with the diagnosis of EPF, women prefer
medical management to surgical when the success rate of
the former exceeds 65 % [7]. We were able to far exceed
this success rate in our routine clinical practice and without
adherence to a strict research protocol. In conclusion, our
results support the use of medical management as a valu-
able non-invasive alternative to surgery in routine clinical
practice. Our findings, furthermore, underscore the
importance of formally educating caregivers regarding the
expected findings, expected pain, patterns of bleeding fol-
lowing administration of medications and ultrasound
interpretation to optimize treatment success.
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